Univariate analysis of allografted patients
| Classification . | N (%) . | PFS . | OS . | ||
|---|---|---|---|---|---|
| No. (%) of events (1.5-y survival) . | P (log-rank) . | No. (%) of events (1.5-y survival) . | P (log-rank) . | ||
| All | 104 (100) | 70 (35.3) | 48 (62.0) | ||
| Status at alloSCT* | < .001; .008† | .002; .074† | |||
| CR | 21 (20.2) | 7 (65.8) | 4 (85.2) | ||
| PR | 46 (44.2) | 33 (36.1) | 19 (61.0) | ||
| SD, PD | 36 (34.6) | 30 (14.1) | 25 (48.7) | ||
| Time from autoSCT to relapse | .465 | .979 | |||
| 12 mo or less | 75 (72.1) | 52 (34.1) | 34 (59.9) | ||
| More than 12 mo | 29 (27.9) | 19 (38.4) | 14 (67.4) | ||
| Donor type | .619 | .145 | |||
| Sibling | 57 (54.8) | 40 (33.2) | 23 (67.7) | ||
| Matched unrelated donor | 33 (31.7) | 21 (41.7) | 17 (57.1) | ||
| Haploidentical | 14 (13.5) | 10 (28.6) | 8 (50.0) | ||
| GVHD | .024 | < .001 | |||
| Acute | 28 (26.9) | 23 (21.4) | 18 (46.4) | ||
| Chronic | 37 (41.1) | 22 (53.1) | 9 (88.7) | ||
| No | 39 (37.5) | 26 (27.8) | 21 (46.9) | ||
| Classification . | N (%) . | PFS . | OS . | ||
|---|---|---|---|---|---|
| No. (%) of events (1.5-y survival) . | P (log-rank) . | No. (%) of events (1.5-y survival) . | P (log-rank) . | ||
| All | 104 (100) | 70 (35.3) | 48 (62.0) | ||
| Status at alloSCT* | < .001; .008† | .002; .074† | |||
| CR | 21 (20.2) | 7 (65.8) | 4 (85.2) | ||
| PR | 46 (44.2) | 33 (36.1) | 19 (61.0) | ||
| SD, PD | 36 (34.6) | 30 (14.1) | 25 (48.7) | ||
| Time from autoSCT to relapse | .465 | .979 | |||
| 12 mo or less | 75 (72.1) | 52 (34.1) | 34 (59.9) | ||
| More than 12 mo | 29 (27.9) | 19 (38.4) | 14 (67.4) | ||
| Donor type | .619 | .145 | |||
| Sibling | 57 (54.8) | 40 (33.2) | 23 (67.7) | ||
| Matched unrelated donor | 33 (31.7) | 21 (41.7) | 17 (57.1) | ||
| Haploidentical | 14 (13.5) | 10 (28.6) | 8 (50.0) | ||
| GVHD | .024 | < .001 | |||
| Acute | 28 (26.9) | 23 (21.4) | 18 (46.4) | ||
| Chronic | 37 (41.1) | 22 (53.1) | 9 (88.7) | ||
| No | 39 (37.5) | 26 (27.8) | 21 (46.9) | ||
PFS indicates progression-free survival; OS, overall survival; alloSCT, allogeneic transplantation; autoSCT, autologous transplantation; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; and GVHD, graft-versus-host disease.
The sum does not add to the total because of missing data.
P value is associated at the comparison for CR versus PR.